Clinical trials: Influenza Vaccines
Influenza
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' influenza investigational vaccine GSK2340274A in healthy Japanese adults aged 20-64 years.
- Trial name
- NCT00989612
- Testing
- Influenza investigational vaccine GSK2340274A
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Assessment of the Clinical Performance of the ARROW-FLU System
The ARROW-FLU Influenza A\&B Test is an in vitro diagnostic immuno-chromatographic assay intended for the qualitative detection of influenza A and influenza B viral nucleoprotein antigens from nasal or nasopharyngeal swab…
- Trial name
- NCT02996136
- Testing
- Flu Symptoms
- Where
- 14 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Sekisui Diagnostics, LLC
covid19 Infection, Influenza, Human
Covid-19 and Influenza Oral Vaccine Study
The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery.
- Trial name
- NCT06355232
- Testing
- Covid-19 vaccine, Influenza vaccine
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Influenza
Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children
A study to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V is as immunogenic as a locally sourced competitor vaccine in young children.
- Trial name
- NCT01310400
- Testing
- Inflexal V, Agrippal
- Where
- China
- Volunteers
- 1,356 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Enterovirus Infections, Influenza
Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine
Subjects will be recruited and divided into 3 groups: 1. Experimental Group (378 subjects): combined immunization of EV71 vaccine and influenza vaccine; 2. Control Group A (378 subjects): EV71 vaccine only; 3.
- Trial name
- NCT04091880
- Testing
- EV71 vaccine and influenza vaccine, EV71 vaccine, influenza vaccine
- Where
- China
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Influenza, Human
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control…
- Trial name
- NCT00644059
- Testing
- Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
- Where
- 101 sites in Finland, Germany and 1 more
- Volunteers
- 4,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine
The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (TIV) in elderly subjects.
- Trial name
- NCT01767896
- Testing
- ASP7374, approved egg-derived TIV
- Where
- 3 sites in Japan
- Volunteers
- 1,020 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Human, Influenza
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above
This protocol was designed to evaluate the safety, clinical tolerability and immunogenicity of the Trivalent Influenza Virus Vaccine (TIVf, purified surface antigen, inactivated, egg derived), Northern Hemisphere formulation…
- Trial name
- NCT01640327
- Testing
- Trivalent influenza virus vaccine (TIVf)
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Human
A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers
This is a study in healthy adult volunteers to assess the bioequivalence of over-encapsulated oseltamivir capsules to commercially available oseltamivir capsules. Both formulations will be administered in the fasting state.
- Trial name
- NCT01258530
- Testing
- over-encapsulated oseltamivir, oseltamivir
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
The aim of the study was to describe the safety and immunogenicity of a 0.5-mL dose (15 μg hemagglutinin [HA] per strain) of Fluzone Quadrivalent vaccine in children 6 to <36 months of age.
- Trial name
- NCT02915302
- Testing
- Fluzone Quadrivalent vaccine, No Preservative
- Where
- 36 sites in United States, United Kingdom
- Volunteers
- 1,950 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1.
- Trial name
- NCT01773928
- Testing
- Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
- Where
- 20 sites in United States
- Volunteers
- 1,928 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza, Human
Relenza® Sentinel Site Monitoring Program in Japan
To collect background information of patients receiving a prescription for Relenza® and study risk factors etc. for adverse drug reactions collected through spontaneous reporting.
- Trial name
- SSMP (NCT01199744)
- Testing
- zanamivir
- Volunteers
- 1,575 people
- Sponsor
- GlaxoSmithKline
COVID-19 Respiratory Infection, Influenza A
Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit
To compare the results obtained by analysis of a self-collected anterior nasal (AN) swab as part of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit to a healthcare provider (HCP)-collected AN swab in patients with symptoms…
- Conditions
- COVID-19 Respiratory Infection, Influenza A, Influenza Type B, RSV Infection
- Trial name
- NCT06008457
- Testing
- Labcorp COVID-19+Flu+RSV Test Home Collection Kit
- Where
- United States
- Volunteers
- 1,600 people
- Sponsor
- Sequenom, Inc.
Influenza
Cost of Illness Associated With Influenza in the UK
The objective of this study is to describe the burden associated with influenza in the UK, from both primary and secondary care perspectives, and to stratify the burden by the annual degree of mismatch between predicted and…
- Trial name
- NCT01521416
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Influenza
A Multicenter, Double-blind, Parallel Phase III Study
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III
- Trial name
- NCT02352584
- Testing
- GC3110A(Quadrivalent), GC Flu(Trivalent), GC3110A(Trivalent)
- Where
- South Korea
- Volunteers
- 1,299 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to <1 year with influenza like symptoms
- Trial name
- NCT03653364
- Testing
- Baloxavir Marboxil
- Where
- 27 sites in United States, Bulgaria and 7 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Influenza, Influenza -Like Illness
Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness
This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory…
- Trial name
- NCT04610047
- Testing
- Norketotifen
- Where
- 20 sites in United States
- Volunteers
- 315 people
- Sponsor
- Emergo Therapeutics, Inc.
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 60 years of age.
- Trial name
- NCT02177734
- Testing
- Investigational H7N9 vaccine GSK3277510A, Investigational H7N9 vaccine GSK3277509A
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Avian
Recombinant H7 Hemagglutinin Influenza Vaccine Trial
Recombinant H7 (rH7) vaccine has been shown to be poorly immunogenic in previous human clinical trials. This study will test approaches to improve the immunogenicity of H7 vaccine, namely use of a three dose regimen, use of a…
- Trial name
- FLU007 (NCT03038776)
- Testing
- Recombinant influenza hemagglutinin
- Where
- Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Healthy
Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males
Research Hypothesis: VGX-3400 (DNA plasmids encoding the hemagglutinin (HA), neuraminidase (NA), and M2e-NP antigen of the H5N1 avian influenza virus) administered to healthy adult males by IM injection followed by EP will be…
- Trial name
- NCT01184976
- Testing
- VGX-3400
- Where
- 2 sites in South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.